F. Stephen Hodi
Scientist
Ludwig Center at Harvard
Harvard University
United States of America
Biography
My primary research interest is in cancer immunotherapy, particularly the development of immune checkpoint inhibitors. My contributions to the field include the first human trials of ipilimumab, a fully human monoclonal antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4) and, later, the phase III registration study of the same agent. Subsequently, I have continued as a key investigator in the clinical development of the second family of checkpoint inhibitors, anti-PD-1 and anti-PD-L1. A primary focus of my work now involves combinatorial approaches to treatment, combining immune checkpoint blockade with other therapies, including targeted therapies, cytokine therapies and angiogenesis inhibitors. Further, a Phase III trial I led with Jedd Wolchok of Ludwig MSK recently led to the approval of a checkpoint combination, which pairs anti-CTLA-4 and anti-PD-1 therapy for the treatment of melanoma. I am director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women's Cancer Center and an Assistant Professor of medicine at Harvard Medical School.
Research Interest
Cancer immunotherapy, human monoclonal antibody, cytokine cancer therapies
Publications
-
Wu X, Giobbie-Hurder A, Liao X, Connelly C, Connolly EM, Li J, Manos MP, Lawrence D, McDermott D, Severgnini M, Zhou J, Gjini E, Lako A, Lipschitz M, Pak CJ, Abdelrahman S, Rodig S, Hodi FS. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Cancer Immunol Res 2016; 5:17-28.
-
De Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res 2017; 5:312-318.
-
Wang DY, Eroglu Z, Ozgun A, Leger PD, Zhao S, Ye F, Luke JJ, Joseph RW, Haq R, Ott PA, Hodi FS, Sosman J, Johnson DB, Buchbinder EL. Clinical features of acquired resistance to anti-PD-1 therapy in advanced melanoma. Cancer Immunol Res 2017.
-
Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A, Spektor A, Krishnan M, Ott PA, Balboni TA, Hodi FS, Schoenfeld JD. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys 2017; 98:344-351.
